InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,001.35
(
0.10%
)
US TECH 100
20,548.00
(
-0.03%
)
Dow Jones
44,293.13
(
0.69%
)
Brent Oil
72.12
(
0.40%
)
Bitcoin
88,289.09
(
-0.52%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Smilin_B

Send PM Follow Ignore
Followers 1035
Posts 54821
Boards Moderated 0
Alias Born 03/29/2004

Smilin_B

Re: The_radman post# 37159

Tuesday, 10/13/2009 3:30:05 PM

Tuesday, October 13, 2009 3:30:05 PM

Post# of 58465
hearing GETA/FDA chatter about positive Phase3 results. Evidently their biomarker approach on low-normal LDH has achieved the holy grail p-value of 0.05 that [FDA] is looking for to approve the drug

What will be the new target on GETA if this is validated?

If the Genasense trial is a success, Genta will displace Vanda Pharmaceuticals(VNDA) as the most shocking, long shot of long shots winner in biotech this year.
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up